# PLRX (Pliant Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Pliant Therapeutics, Inc. reported $0 in revenue and a net loss of $90.36M for the fiscal year ended December 31, 2025.

- Canonical: https://convexityos.com/fundamentals/PLRX
- Markdown: https://convexityos.com/fundamentals/PLRX.md
- SEC CIK: 0001746473
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:53 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001746473&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $0 | Dec 31, 2025 |
| Operating Income | FY 2025 | -$94.95M | Operating profit |
| Net Income | FY 2025 | -$90.36M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$1.46 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$66.79M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $141.1M | Total debt: $27.78M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $1.58M | $9.69M | $7.57M | $41.82M | $57.05M |
| Research & Development | $109.2M | $169.3M | $127.8M | $96.94M | $77.55M | $66.19M | $47.35M |
| Total Operating Expenses | $156.4M | $228.4M | $185.7M | $136.9M | $105.1M | $83.46M | $58.28M |
| **Operating Income** | -$156.4M | -$228.4M | -$184.1M | -$127.2M | -$97.53M | -$41.65M | -$1.23M |
| **EBITDA** | -$154.7M | -$226.2M | -$182.3M | -$125.4M | -$96.00M | -$40.34M | -$118K |
| Interest Income | -- | -- | -- | -- | -- | $478K | $816K |
| Interest Expense | $2.56M | $3.02M | $1.27M | $791K | $0 | -- | -- |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$149.3M | -$210.3M | -$161.3M | -$123.3M | -$97.26M | -$41.53M | -$631K |
| Basic EPS | -$2.43 | -$3.47 | -$2.75 | -$2.94 | -$2.71 | -$1.95 | -$4.22 |
| **Diluted EPS** | -$2.43 | -$3.47 | -$2.75 | -$2.94 | -$2.71 | -$1.95 | -$4.22 |
| Basic Shares Outstanding | 61.4M | 60.5M | 58.7M | 42.0M | 35.8M | 21.3M | 1.6M |
| Diluted Shares Outstanding | 61.4M | 60.5M | 58.7M | 42.0M | 35.8M | 21.3M | 1.6M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | -- | -- | -- | -- | -- | -- | $0 |
| Research & Development | $17.93M | $16.73M | $13.58M | $15.59M | $17.94M | $32.20M | $43.44M | $38.79M |
| Total Operating Expenses | $25.74M | $23.86M | $21.77M | $23.58M | $28.27M | $45.59M | $58.94M | $53.32M |
| **Operating Income** | -$25.74M | -$23.86M | -$21.77M | -$23.58M | -$28.27M | -$45.59M | -$58.94M | -$53.32M |
| **EBITDA** | -$25.54M | -$23.66M | -$21.51M | -$23.21M | -$27.87M | -$45.19M | -$58.49M | -$52.86M |
| Interest Expense | $0 | $0 | $0 | $136K | $815K | $809K | $799K | $834K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$24.38M | -$22.37M | -$20.04M | -$23.58M | -$26.30M | -$43.30M | -$56.17M | -$49.73M |
| Basic EPS | -$0.39 | -$0.36 | -$0.32 | -- | -$0.43 | -$0.71 | -$0.92 | -- |
| **Diluted EPS** | -$0.39 | -$0.36 | -$0.32 | -- | -$0.43 | -$0.71 | -$0.92 | -- |
| Basic Shares Outstanding | 61.9M | 61.9M | 61.8M | -- | 61.4M | 61.4M | 61.2M | -- |
| Diluted Shares Outstanding | 61.9M | 61.9M | 61.8M | -- | 61.4M | 61.4M | 61.2M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $45.45M | $71.19M | $63.23M | $33.69M | $51.66M | $50.88M | $85.81M |
| Short-Term Investments | $145.5M | $284.5M | $431.0M | $297.5M | $148.9M | $226.0M | $16.97M |
| **Cash & Short-Term Investments** | $190.9M | $355.7M | $494.2M | $331.2M | $200.6M | $276.9M | $102.8M |
| Accounts Receivable, Net | -- | -- | $0 | $1.98M | $2.00M | $9.28M | $7.05M |
| **Total Current Assets** | $196.4M | $362.3M | $505.5M | $340.3M | $209.4M | $290.8M | $111.9M |
| Property, Plant & Equipment, Net | $2.94M | $5.53M | $3.57M | $4.49M | $4.61M | $4.32M | $4.08M |
| Other Non-Current Assets | $392K | $435K | $392K | $394K | $838K | $451K | $3.08M |
| **Total Non-Current Assets** | $28.78M | $34.69M | $6.65M | $10.30M | $11.77M | $4.77M | $7.16M |
| **Total Assets** | $225.2M | $396.9M | $512.2M | $350.6M | $221.2M | $295.5M | $119.1M |
| Accounts Payable | $480K | $5.96M | $4.53M | $1.58M | $2.97M | $2.02M | $1.25M |
| **Total Current Liabilities** | $16.36M | $33.22M | $28.52M | $23.91M | $16.83M | $11.60M | $8.17M |
| Long-Term Debt | $0 | $30.21M | $10.05M | $9.93M | $0 | -- | -- |
| Other Non-Current Liabilities | -- | -- | -- | -- | $0 | $866K | $912K |
| **Total Non-Current Liabilities** | $27.66M | $59.65M | $10.05M | $13.36M | $5.33M | $866K | $912K |
| **Total Liabilities** | $44.02M | $92.87M | $38.58M | $37.27M | $22.16M | $12.46M | $9.08M |
| **Total Debt (incl. Leases)** | $29.11M | $60.19M | $11.37M | $15.81M | $7.19M | -- | -- |
| Common Stock | $6.0K | $6.0K | $6.0K | $5.0K | $3.0K | $3.0K | $1.0K |
| Retained Earnings | -$859.4M | -$710.1M | -$499.7M | -$338.4M | -$215.1M | -$117.8M | -$76.30M |
| Accumulated Other Comp. Income | -$15K | $321K | $345K | -$1.96M | -$201K | -$32K | -$1.0K |
| **Total Stockholders' Equity** | $181.2M | $304.1M | $473.6M | $313.3M | $199.1M | $283.1M | -$76.30M |
| Total Equity | $181.2M | $304.1M | $473.6M | $313.3M | $199.1M | $283.1M | -$76.30M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $26.57M | $24.88M | $22.19M | $45.45M | $93.73M | $86.82M | $91.94M | $71.19M |
| Short-Term Investments | $114.5M | $133.2M | $148.7M | $145.5M | $148.1M | $176.1M | $213.7M | $284.5M |
| **Cash & Short-Term Investments** | $141.1M | $158.1M | $170.9M | $190.9M | $241.8M | $262.9M | $305.6M | $355.7M |
| **Total Current Assets** | $144.2M | $163.1M | $174.9M | $196.4M | $245.6M | $267.4M | $311.2M | $362.3M |
| Property, Plant & Equipment, Net | $2.18M | $2.41M | $2.66M | $2.94M | $4.34M | $4.89M | $5.24M | $5.53M |
| Other Non-Current Assets | $568K | $554K | $389K | $392K | $392K | $391K | $427K | $435K |
| **Total Non-Current Assets** | $25.67M | $26.74M | $27.67M | $28.78M | $31.01M | $32.38M | $33.58M | $34.69M |
| **Total Assets** | $169.9M | $189.9M | $202.6M | $225.2M | $276.6M | $299.8M | $344.8M | $396.9M |
| Accounts Payable | $3.07M | $1.53M | $362K | $480K | $485K | $1.38M | $5.62M | $5.96M |
| **Total Current Liabilities** | $17.92M | $16.48M | $10.36M | $16.36M | $17.62M | $20.59M | $28.20M | $33.22M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $30.44M | $30.36M | $30.28M | $30.21M |
| **Total Non-Current Liabilities** | $25.32M | $26.47M | $27.07M | $27.66M | $58.67M | $59.15M | $59.40M | $59.65M |
| **Total Liabilities** | $43.24M | $42.95M | $37.43M | $44.02M | $76.29M | $79.74M | $87.61M | $92.87M |
| **Total Debt (incl. Leases)** | $27.78M | $28.74M | $28.78M | $29.11M | $59.86M | $60.38M | $60.17M | $60.19M |
| Common Stock | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K |
| Retained Earnings | -$926.2M | -$901.8M | -$879.4M | -$859.4M | -$835.8M | -$809.5M | -$766.2M | -$710.1M |
| Accumulated Other Comp. Income | -$530K | -$397K | -$341K | -$15K | $34K | -$1.0K | $159K | $321K |
| **Total Stockholders' Equity** | $126.6M | $146.9M | $165.2M | $181.2M | $200.3M | $220.1M | $257.2M | $304.1M |
| Total Equity | $126.6M | $146.9M | $165.2M | $181.2M | $200.3M | $220.1M | $257.2M | $304.1M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$149.3M | -$210.3M | -$161.3M | -$123.3M | -$97.26M | -$41.53M | -$631K |
| Depreciation & Amortization | $1.70M | $2.12M | $1.84M | $1.82M | $1.53M | $1.31M | $1.11M |
| Stock-Based Compensation | $26.23M | $37.63M | $44.48M | $22.60M | $10.44M | $3.90M | $1.83M |
| Change in Receivables | -- | $0 | $1.98M | $15K | $7.28M | -$2.23M | -$7.05M |
| Change in Payables | -$5.48M | $1.43M | $2.97M | -$1.35M | $891K | $922K | -$1.25M |
| **Operating Cash Flow** | -$128.3M | -$155.5M | -$116.4M | -$94.63M | -$75.44M | -$37.27M | -$2.75M |
| Capital Expenditure | -$374K | -$3.85M | -$921K | -$1.76M | -$1.95M | -$1.53M | -$964K |
| **Free Cash Flow** | -$128.7M | -$159.4M | -$117.3M | -$96.39M | -$77.40M | -$38.80M | -$3.71M |
| **Investing Cash Flow** | $134.3M | $140.3M | -$127.0M | -$150.2M | $73.70M | -$210.9M | -$17.93M |
| **Financing Cash Flow** | -$31.70M | $23.12M | $274.4M | $226.9M | $2.53M | $213.2M | $45.54M |
| **Net Change in Cash** | -$25.74M | $7.95M | $31.03M | -$17.98M | $783K | -$34.92M | $24.86M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$24.38M | -$22.37M | -$20.04M | -$23.58M | -$26.30M | -$43.30M | -$56.17M | -$49.73M |
| Depreciation & Amortization | $200K | $200K | $264K | $365K | $400K | $400K | $448K | $458K |
| Stock-Based Compensation | $4.15M | $4.19M | $4.25M | $4.53M | $6.42M | $6.38M | $8.91M | $8.42M |
| Change in Receivables | -- | -- | -- | -- | -- | -- | -- | $0 |
| Change in Payables | $1.54M | $1.17M | -$118K | -$3.0K | -$897K | -$4.24M | -$338K | -$930K |
| **Operating Cash Flow** | -$16.98M | -$12.80M | -$19.23M | -$17.79M | -$21.08M | -$40.60M | -$48.86M | -$47.66M |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 | -$112K | -$262K | -$209K |
| **Free Cash Flow** | -$16.98M | -$12.80M | -$19.23M | -$17.79M | -$21.08M | -$40.72M | -$49.13M | -$47.87M |
| **Investing Cash Flow** | $18.60M | $15.49M | -$4.10M | $1.77M | $27.92M | $35.49M | $69.11M | $39.13M |
| **Financing Cash Flow** | $64K | $0 | $74K | -$32.27M | $72K | $0 | $498K | $102K |
| **Net Change in Cash** | $1.69M | $2.69M | -$23.25M | -$48.29M | $6.91M | -$5.12M | $20.75M | -$8.43M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -- | -11654.7% | -1313.4% | -1288.1% | -99.6% | -2.2% |
| **Net Profit Margin** | -- | -- | -10211.1% | -1273.3% | -1284.5% | -99.3% | -1.1% |
| Return on Equity (ROE) | -82.4% | -69.2% | -34.1% | -39.4% | -48.9% | -14.7% | -- |
| Return on Assets (ROA) | -66.3% | -53.0% | -31.5% | -35.2% | -44.0% | -14.1% | -0.5% |
| Current Ratio | 12.00x | 10.91x | 17.72x | 14.23x | 12.44x | 25.07x | 13.69x |
| Quick Ratio | 11.67x | 10.71x | 17.33x | 13.93x | 12.04x | 24.67x | 13.44x |
| Debt to Equity | 0.16x | 0.20x | 0.02x | 0.05x | 0.04x | -- | -- |
| **Revenue Growth (YoY)** | -- | -100.0% | -83.7% | +27.9% | -81.9% | -26.7% | -- |
| 5Y Revenue / Share Growth | -100.0% | -100.0% | -- | -- | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -71.4% | -62.8% | -68.5% | -82.4% | -87.6% | -94.0% | -85.4% | -69.2% |
| Return on Assets (ROA) | -53.2% | -48.6% | -55.9% | -66.3% | -63.4% | -69.0% | -63.7% | -53.0% |
| Current Ratio | 8.05x | 9.90x | 16.89x | 12.00x | 13.93x | 12.99x | 11.03x | 10.91x |
| Quick Ratio | 7.87x | 9.59x | 16.50x | 11.67x | 13.72x | 12.77x | 10.84x | 10.71x |
| Debt to Equity | 0.22x | 0.20x | 0.17x | 0.16x | 0.30x | 0.27x | 0.23x | 0.20x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
